OR WAIT null SECS
Bringing the number of Synexus’ Dedicated Research Centres to seventeen is its recently completed purchase of CLCC which has centers in the major conurbations of Warsaw, Gdynia and Katowice. These centers will work closely with Synexus’ Polish clinical trial centre in Wroclaw.
Michael Fort, Chief Executive of Synexus commented “This acquisition provides us with access to millions more patients and a wider range of therapy areas. The Synexus model continues to gain ground with our clients in pharma who recognize the benefits that the streamlined recruitment processes the Dedicated Research Centres deliver, namely helping to speed up trials, reduce costs and drive up quality. We are actively looking for further acquisitions, and in particular to increase our presence in India. These new centers will ensure that our growth in 2008 will be repeated in 2009."
Dr Andrzej Opadczuk, who previously owned CLCC, will continue to manage the centres and will report to Synexus CEE Vice President, Dr Christian Tueni. The management of the new centers will be trained in the Synexus Quality Assurance System and will follow the worldwide SOPs which ensure that all Synexus Dedicated Research Centres offer the same high level of good clinical practice and patient care. The centers will change their name to Synexus immediately.